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Background 
•  Non-Alcoholic Fatty Liver Disease (NAFLD) affects 
more than 90% of patients with morbid obesity 
(MO).  
•  NAFLD includes a spectrum of disease that begins 
with simple steatosis (fatty change), then 
steatohepatitis (NASH) in 10-15% and eventually 
cirrhosis in 3-8%.  
•  Liver biopsy is the gold standard for diagnosis of 
NASH and stages of fibrosis and cirrhosis; however, 
several non-invasive blood tests have 
demonstrated an ability to predict the presence or 
absence of significant liver fibrosis in hepatitis.  
Objectives  
•  To determine the ability of non-invasive blood tests 
(NAFLD, BARD, Fib-4, APRI) to predict liver biopsy 
findings of significant  fibrosis (SF) vs no significant 
fibrosis (NSF) specifically in patients with MO.  
Design 
v Liver biopsies from patients with MO undergoing 
gastric bypass surgery were studied retrospectively.  
Inclusion criteria :  
•  BMI ≥ 40 kg/m2 or > 35 kg/m2 with Diabetes or 
hypertension 
•  Availability of data concerning sex, age, BMI, 
Diabetes, platelet count, AST, ALT and albumin 
within 6 months preceding surgery   
Exclusion criteria :  
•  Any other potential cause of liver pathology  
v Test cut-off scores for SF were set using available 
on-line calculators.  
 
•  No single non-invasive test showed sufficient 
sensitivity and specificity to recommend it.  
•  Sequential combinations of these non-invasive test 
results might improve their predictive value.  
•  Diabetes was associated with SF in patients with 
MO and is likely to be a risk factor for progressive 
liver fibrosis. 
 
Results 
Conclusion 
Blood  
Test Parameters  Sensitivity  Specificity  
NAFLD 
Age, BMI, AST, 
ALT,  Platelet, 
Albumin, DM 
41.9% (13/31) 86.29% (107/124 ) 
BARD BMI,AST, ALT, DM 90.3% (28/31) 29.8% (37/124 ) 
FIB-4 Age, AST, ALT, Platelet  
3.23% (1/31)  
 100% (124/124) 
APRI AST Platelet 16% (5/31) 99% (123/124) 
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